Viatris Inc (VTRS)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$18.66
▲ +0.44 (2.41%)
Fair valueUndervalued
$37 +96.8% to fair value
$18fair band $22–$51$55
Day's range
$18.15 – $18.67
52-week range
$9.58 – $18.67
About Viatris Inc
Generic medicines, branded medicines that have lost patent protection and biosimilars are supplied by Viatris, a global healthcare company. Its portfolio includes well-known brands such as Lipitor and Viagra, and it also makes the EpiPen auto-injector. Customers are pharmacies, wholesalers, hospitals, health systems and governments in many countries. The business is organised by geographic region, and it runs a large manufacturing and distribution network.
High volumes of generic and established branded medicines generated revenue of $14.7 billion over the last twelve months. Revenue has changed at -4.2% a year across the last three years. The operating margin is -0.6%, and the business earns -0% on the capital invested in it, which is effectively nothing. Net debt is 4.6 times EBITDA, and the dividend yield is 2.6%. On the site's X-Ray Score it receives 26 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $9.58 – $18.67Volume 9,421,300Daily, split-adjusted
Vitals
Market cap$21.7B
52-week range$9.58 – $18.67
Volume (last day)9,421,300
P/E (TTM)–
EBIT / EV yield-0.3%
Free-cash-flow yield9.0%
Dividend yield2.6%
Revenue (TTM)$14.7B
Net income (TTM)–
Operating margin-0.6%
Return on capital-0.3%
Debt incl. leases$13.4B
Cash & securities$887M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$37
Undervalued
+96.8% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Loss-making or insufficient history: no DCF/EPV
Price $19
Undervalued < $22Fair $22 – $51Overvalued > $51
Peer multiples
$37
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, but the price is low
Our models put fair value above today's price, but models can be wrong, so check the business first. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
63/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield-0.3%
Free-cash-flow yield9.0%
Fair value vs price2.0×
Growth
Weak
8/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-4.2%
Growth consistency40%
Profitability
Weak
8/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital-0.3%
Operating margin-0.6%
Gross profitability14.6%
Financial health
Weak
13/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score3 / 9
Net debt / EBITDA4.6×
Interest cover-0.2×
Dividends
Weak
44/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield2.6%
Dividends vs free cash flow29%
Quarterly results: last 6 quarters
-11.2%
Mar '25
-5.6%
Jun '25
+0.2%
Sep '25
+5.0%
Dec '25
+8.1%
Mar '26
+4.9%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $3.8B, diluted EPS $-0.10.
Compare with peers
ZTS Zoetis Inc.68 LLY ELI LILLY & Co61 BMY Bristol Myers Squibb C...59 JNJ Johnson & Johnson50Other Pharmaceuticals companies by X-Ray Score.
Fundamentals checklist
● 2 Good · ● 1 Average · ● 11 BadCash quality
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreBad
Growth
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceGood
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 31/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Operating income | −$34M | $1.6B | $766M | $10M | −$2.7B |
| Net income | −$1.3B | $2.1B | $55M | −$634M | −$3.5B |
| Operating cash flow | $3.0B | $3.0B | $2.9B | $2.3B | $2.3B |
| Operating margin | -0.2% | 9.9% | 5.0% | 0.1% | -18.6% |
| Free cash flow | $2.6B | $2.6B | $2.5B | $2.0B | $1.9B |
| Diluted EPS | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 0 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 17.68 | Bullish |
| EMA 10 | 17.81 | Bullish |
| SMA 20 | 17.63 | Bullish |
| EMA 20 | 17.59 | Bullish |
| SMA 50 | 16.95 | Bullish |
| EMA 50 | 17.17 | Bullish |
| SMA 100 | 16.69 | Bullish |
| EMA 100 | 16.59 | Bullish |
| SMA 200 | 15.43 | Bullish |
| EMA 200 | 15.34 | Bullish |
Oscillators (daily)
| RSI (14) | 69.24 | Neutral |
| MACD (12, 26) | 0.27 | Bullish |
| Momentum (12) | 5.30 | Bullish |
| Stochastic %K (14) | 99.44 | Bearish |
| Williams %R (14) | -0.56 | Bearish |
| CCI (20) | 217.3 | Bearish |
Pivot points (classic, last session)
S3 17.80 | S2 17.97 | S1 18.32 | Pivot 18.49 | R1 18.84 | R2 19.01 | R3 19.36 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.48 USD
Yield on today's price
2.57%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 21 Aug 2026 | 0.1200 |
| 22 May 2026 | 0.1200 |
| 9 Mar 2026 | 0.1200 |
| 24 Nov 2025 | 0.1200 |
| 22 Aug 2025 | 0.1200 |
| 23 May 2025 | 0.1200 |
| 10 Mar 2025 | 0.1200 |
| 22 Nov 2024 | 0.1200 |
| 23 Aug 2024 | 0.1200 |
| 23 May 2024 | 0.1200 |
| 8 Mar 2024 | 0.1200 |
| 22 Nov 2023 | 0.1200 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
VTRS SEC filings
8 Oct 2026
8-KSEC EDGAR
Entered a material agreement; Other events
6 Aug 2026
10-QSEC EDGAR
Quarterly report
6 Aug 2026
8-KSEC EDGAR
Results of operations; Other events
1 Jul 2026
8-KSEC EDGAR
Entered a material agreement
18 Jun 2026
8-KSEC EDGAR
Entered a material agreement
15 Jun 2026
8-KSEC EDGAR
Other events
15 Jun 2026
424B5SEC EDGAR
424B5
12 Jun 2026
424B5SEC EDGAR
424B5
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.